Journal of the cardiometabolic syndrome最新文献_第6页

Insulin Resistance and Cardiometabolic Syndrome 胰岛素抵抗和心脏代谢综合征

Journal of the cardiometabolic syndrome Pub Date : 2021-02-03 DOI: 10.51789/CMSJ.2021.1.E9

Jeong-a Kim

引用次数: 1

The Interactive Cardiovascular Risk Factor: Socioeconomic Status and Metabolic Syndrome 相互作用的心血管危险因素:社会经济地位和代谢综合征

Journal of the cardiometabolic syndrome Pub Date : 2021-01-01 DOI: 10.51789/cmsj.2021.1.e22

Mi-Na Kim

引用次数: 0

Cardiometabolic HFpEF: Mechanisms and Therapies 心脏代谢HFpEF:机制和治疗

Journal of the cardiometabolic syndrome Pub Date : 2021-01-01 DOI: 10.51789/cmsj.2021.1.e18

G. Schiattarella, Joseph A. Hill

{"title":"Cardiometabolic HFpEF: Mechanisms and Therapies","authors":"G. Schiattarella, Joseph A. Hill","doi":"10.51789/cmsj.2021.1.e18","DOIUrl":"https://doi.org/10.51789/cmsj.2021.1.e18","url":null,"abstract":"Heart failure with preserved ejection fraction (HFpEF) accounts for at least half of all patients with heart failure (HF) and is projected to be the most common form of HF in the near feature. HFpEF, characterized by high morbidity and mortality, poses an enormous medical and societal burden and lacks evidence-based therapies. Hence, HFpEF has been recognized as the greatest unmet need in cardiovascular medicine. HFpEF is a heterogenous syndrome presenting as several different clinical phenotypes. Among these, metabolic alterationdriven HFpEF—i.e. cardiometabolic HFpEF—is emerging around the globe as the most prevalent form of HFpEF. Pathophysiological mechanisms of cardiometabolic HFpEF are still incompletely understood. However, recent advances in the preclinical modeling of the syndrome, coupled with better definition of its clinical presentations and analysis of human HFpEF myocardial specimens, have unveiled metabolic disturbances and inflammatory burden as 2 key drivers of HFpEF pathophysiology. Here, we summarize evidence in support of a cardiometabolic phenotype of HFpEF and discuss the pivotal biological mechanisms underlying this syndrome in the hope of informing more efficacious therapeutic approaches in the future.","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"2017 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88638424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiorespiratory Fitness, Metabolic Syndrome and Mortality in Adults 成人心肺健康、代谢综合征和死亡率

Journal of the cardiometabolic syndrome Pub Date : 2021-01-01 DOI: 10.51789/cmsj.2021.1.e20

SoJung Lee

引用次数: 0

Cardiovascular Disease Prediction Model in Patients with Hypertension Using Deep Learning: Analysis of the National Health Insurance Service Database from Republic of Korea 使用深度学习的高血压患者心血管疾病预测模型:对韩国国民健康保险服务数据库的分析

Journal of the cardiometabolic syndrome Pub Date : 2021-01-01 DOI: 10.51789/cmsj.2021.1.e19

Y. Choi, Hoyeon Jeong, Jun Hyeok Lee, K. Sung, J. Shin, H. Kim, J. Kim, D. Kang

引用次数: 2

Pulse Pressure and the Metabolic Syndrome in Patients With Hypertension 高血压患者脉压与代谢综合征的关系

Journal of the cardiometabolic syndrome Pub Date : 2009-04-13 DOI: 10.1111/j.1559-4572.2008.00041.x

Vivencio Barrios MD, PhD, Carlos Escobar MD, PhD, Rocio Echarri MD, Arantxa Matalí MD

{"title":"Pulse Pressure and the Metabolic Syndrome in Patients With Hypertension","authors":"Vivencio Barrios MD, PhD, Carlos Escobar MD, PhD, Rocio Echarri MD, Arantxa Matalí MD","doi":"10.1111/j.1559-4572.2008.00041.x","DOIUrl":"10.1111/j.1559-4572.2008.00041.x","url":null,"abstract":"The authors examined the clinical profile of the hypertensive population with the metabolic syndrome (MetS) and elevated pulse pressure (PP) in a sample of 5866 patients (3291 women and 2575 men) included in a large hypertension survey performed in primary care setting. Elevated PP was defined as ≥80 mm Hg in women and ≥75 mm Hg in men; 92.7% of women and 87.6% of men had normal PP values. Patients with higher PP levels were older, were more commonly diabetic, and exhibited more frequently target organ damage and associated clinical conditions. Blood pressure was less well controlled in the subgroup of patients with elevated PP: control rates were 4.1% vs 19.2%, P<.001; men, 3.9% vs 19.0%, P<.001; P=NS between sexes. Low-density lipoprotein cholesterol was similarly controlled regardless of PP: control rates were, 17.0% vs 17.8%; in women with high PP vs normal PP and 25.2% vs 25.1% in men with high PP vs normal PP, both P=NS; P<.001 between sexes with high PP. In the patients with high PP, the female subgroup was older, was more obese, and had more left ventricular hypertrophy and fewer associated clinical conditions than did men. The odds ratio of having high PP in women with MetS vs no MetS was 3.13 and in men was 1.9 (both P<.01).","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"4 2","pages":"72-75"},"PeriodicalIF":0.0,"publicationDate":"2009-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00041.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28314174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Change in Hemoglobin A1c and C-Reactive Protein Levels in Patients With Diabetes Mellitus 糖尿病患者血红蛋白A1c和c反应蛋白水平的变化

Journal of the cardiometabolic syndrome Pub Date : 2009-04-13 DOI: 10.1111/j.1559-4572.2008.00042.x

Sameed Ahmed M. Khatana BS, Tracey H. Taveira PharmD, Gaurav Choudhary MD, Charles B. Eaton MD, Wen-Chih Wu MD

{"title":"Change in Hemoglobin A1c and C-Reactive Protein Levels in Patients With Diabetes Mellitus","authors":"Sameed Ahmed M. Khatana BS, Tracey H. Taveira PharmD, Gaurav Choudhary MD, Charles B. Eaton MD, Wen-Chih Wu MD","doi":"10.1111/j.1559-4572.2008.00042.x","DOIUrl":"10.1111/j.1559-4572.2008.00042.x","url":null,"abstract":"The authors studied the effects on C-reactive protein (CRP) levels of an intensive intervention to reduce hemoglobin A1c (HbA1c) among 58 veterans with type 2 diabetes. Weekly group sessions of behavioral and pharmacologic intervention were conducted for 4 weeks at Providence Veterans Affairs Medical Center. Change in cardiovascular risk factors and CRP levels were compared at baseline and 3 months postintervention. There was a significant decrease in HbA1c (−0.7%±1.9%, P<.01), total cholesterol (−20.3±41.1 mg/dL, P=.01), low-density lipoprotein cholesterol (−11.7±31.4 mg/dL, P=.05), systolic blood pressure (−6.9±21.2 mm Hg, P=.03), and diastolic blood pressure (−6.0±10.6 mm Hg, P<.01) over 4 months. There was no significant change in CRP levels (1.1±6.6 mg/L, P=.2). These results suggest that CRP effects may not be adequate to predict changes in cardiovascular risk among diabetic patients and should not be a surrogate for achieving evidence-based goals in traditional cardiovascular risk factors.","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"4 2","pages":"76-80"},"PeriodicalIF":0.0,"publicationDate":"2009-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00042.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28314177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: Part I. Increased Cardiovascular Disease Risk and the Importance of Atherogenic Dyslipidemia in Persons With the Metabolic Syndrome and Type 2 Diabetes Mellitus 肥胖、代谢综合征和2型糖尿病大流行:第一部分:代谢综合征和2型糖尿病患者心血管疾病风险增加和动脉粥样硬化性血脂异常的重要性

Journal of the cardiometabolic syndrome Pub Date : 2009-04-13 DOI: 10.1111/j.1559-4572.2008.00044.x

Henry N. Ginsberg MD, Paul R. MacCallum PhD

引用次数: 260

Left Ventricular Structural and Functional Changes in the Metabolic Syndrome 代谢综合征左心室结构和功能改变

Journal of the cardiometabolic syndrome Pub Date : 2009-04-13 DOI: 10.1111/j.1559-4572.2008.00043.x

Azra Mahmud MD, PhD, Ibrahim Almuntaser MD, Angie Brown MD, Gerard King PhD, Peter Crean MD, John Feely MD

{"title":"Left Ventricular Structural and Functional Changes in the Metabolic Syndrome","authors":"Azra Mahmud MD, PhD, Ibrahim Almuntaser MD, Angie Brown MD, Gerard King PhD, Peter Crean MD, John Feely MD","doi":"10.1111/j.1559-4572.2008.00043.x","DOIUrl":"10.1111/j.1559-4572.2008.00043.x","url":null,"abstract":"To test the hypothesis that the cardiac structural and functional abnormalities of the metabolic syndrome (MS) are independent of body mass index (BMI), 160 untreated patients (aged 47±1 years [mean ± SEM], 53% male) underwent 2-dimensional echocardiography and tissue Doppler imaging and evaluation for MS. Participants with MS and controls were similar in age, BMI, and ejection fraction, but those with MS had greater left ventricular relative wall thickness (RWT) (0.43±0.008 vs 0.39±0.005, P<.001), reduced midwall fractional shortening (MFS) (13%±0.3% vs 14.2%±0.3%, P<.05), and reduced peak mitral annular velocity (Em) (9.9±0.5 vs 12.3±0.5 cm/sec, P<.01) than controls. There was a linear relationship between the number of features of MS and Em velocity (P<.001), RWT (P<.001), and MFS (P<.05). In a stepwise multiple regression analysis adjusting for likely determinants, MS was an independent predictor of Em in addition to age and nonindexed left ventricular mass. MS is associated with left ventricular concentric remodeling and reduced systolic and diastolic function independent of BMI.","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"4 2","pages":"81-88"},"PeriodicalIF":0.0,"publicationDate":"2009-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00043.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28312494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Utility of Aspirin Therapy in Patients With the Cardiometabolic Syndrome and Diabetes 阿司匹林在心血管代谢综合征和糖尿病患者中的应用

Journal of the cardiometabolic syndrome Pub Date : 2009-04-13 DOI: 10.1111/j.1559-4572.2008.00037.x

Michael Gardner MD, John Palmer MD, Camila Manrique MD, Guido Lastra MD, David W. Gardner MD, James R. Sowers MD

{"title":"Utility of Aspirin Therapy in Patients With the Cardiometabolic Syndrome and Diabetes","authors":"Michael Gardner MD, John Palmer MD, Camila Manrique MD, Guido Lastra MD, David W. Gardner MD, James R. Sowers MD","doi":"10.1111/j.1559-4572.2008.00037.x","DOIUrl":"10.1111/j.1559-4572.2008.00037.x","url":null,"abstract":"Paralleling the rise in obesity, the cardiometabolic syndrome is a rapidly growing health problem in the United States. There is a 3-fold increase in the prevalence of coronary heart disease, myocardial infarction, and stroke due to the coagulation, hemodynamic, and metabolic abnormalities seen in these individuals. The use of aspirin for secondary prevention and, to a lesser degree, primary prevention of cardiovascular events is a well-established standard of care. However, in patients with diabetes or the cardiometabolic syndrome, the role of aspirin in prevention of cardiovascular events remains controversial. In this review, the authors examine the clinical trial data on the use of aspirin in diabetes and the cardiometabolic syndrome for cardiovascular protection. They also explore, in addition to aspirin’s effects on platelet aggregation, some of the mechanisms by which aspirin may favorably alter the course of atherosclerosis, effects on endothelial function, and glycemia.","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"4 2","pages":"96-101"},"PeriodicalIF":0.0,"publicationDate":"2009-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00037.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28312496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7